Arterial expression of the plasminogen activator system early after cardiac transplantation

Cardiovascular Research

Volumn 35, Issue 2, 1997, Pages 241-249

  Garvin, Michael R ^a   Labinaz, Marino ^a   Pels, Klaus ^a   Walley, Virginia M ^b   Mizgala, Henry F ^c   O'Brien, Edward R ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Human, coronary artery; Plasminogen; Plasminogen activator inhibitor 1; Urokinase

Indexed keywords

ALTEPLASE; PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CAUSE OF DEATH; CELL MIGRATION; CLINICAL ARTICLE; HEART PRESERVATION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; CORONARY DISEASE; CORONARY VESSELS; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEART TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030850195     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00088-6     Document Type: Article

References (37)

1. Hosenpud JD, Novick RJ, Breen TJ, Daily OP. The Registry of the International Society for Heart and Lung Transplantation: eleventh official report - 1994. J Heart Lung Transplant 1994;13:561-570.
2. O'Neill BJ, Pflugfelder PW, Singh NR, Menkis AH, McKenzie FN, Kostuk WJ. Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantation. Am J Cardiol 1989;63:1221-1226.
3. Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987;76:827-834.
4. Johnson D, Gao S, Schroeder J, DeCampli W, Billingham M. The spectrum of coronary artery pathology in human cardiac allografts. J Heart Transplant 1989;8:349-359.
5. Costanzo-Nordin M. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992;11:S90-S103.
6. Clausell N, Rabinovitch M. Upregulation of fibronectin synthesis by interleukin-1beta in coronary artery smooth muscle cells is associated with the development of the post-cardiac transplant arteriopathy in piglets. J Clin Invest 1993;92:1850-1858.
7. Rabinovitch M, Oho S. Post-cardiac transplant arteriopathy in piglets is associated with fragmentation of elastin and increased activity of a serine elastase. Am J Pathol 1994;145:202-210.
8. Molossi S, Elices M, Arrhenius T, Diaz R, Coulber C, Rabinovitch M. Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J Clin Invest 1995;95:2601-2610.
9. Schwartz SM, deBlois D, O'Brien ER. The intima: soil for atherosclerosis and restenosis. Circ Res 1995;77:445-465.
10. Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-1072.
11. Politis I, Srikandakumar A, Turner JD, Tsang BK, Ainsworth L, Downey BR. Changes in and partial identification of the plasminogen activator and plasminogen activator inhibitor systems during ovarian follicular maturation in the pig. Biol Reprod 1990;43(4):636-642.
12. Schafer B, Maier K, Eickhoff U, Todd R, Kramer M. Plasminogen activation in healing human wounds. Am J Pathol 1994;144:1269-1280.
13. Sappino AP, Busso N, Belin D, Vassali J-D. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987;47:4043-4046.
14. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev 1990;32:319-328.
15. Labarrere CA, Pitts D, Nelson DR, Faulk W. Page vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 1995;333:1111-1116.
16. Labarrere CA, Pitts D, Halbrook H, Faulk WP. Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients. An immunocytochemical study. Circulation 1994;89:1599-1608.
17. Mizgala HE, Gray LH, Ferris JA, Bociek V, Allard P, Davies C. Coronary artery luminal narrowing in the young with sudden unexpected death: a coroner's autopsy study in 350 subjects age 40 years and under. Can J Cardiol 1993;9:33-40.
18. Schuster EH, Griffith LSC, Bulkley BH. Preponderance of acute proximal left anterior descending coronary artery lesions in fatal myocarial infarction. Am J Cardiol 1981;47:1189-1196.
19. O'Brien ER, Bennett KL, Garvin MR, Zderic TW, Hinohara T, Simpson JB, Kimura T, et al. Big-h3, a TGF-beta inducible gene, is over-expressed in atherosclerotic and restenotic human vascular lesions. Arterioscler Thromb Vasc Biol 1996;16:576-584.
20. Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F. Identification and primary sequence of an unspliced human urokinase poly(A) + RNA. Proc Natl Acad Sci USA 1984;81:4727-4731.
21. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Neilsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;41:139-264.
22. O'Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM, Giachelli CM. Osteopontin is synthesized by macrophage, smooth muscle and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994;145(4):883-894.
23. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1432-1443.
24. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995;15:1444-1455.
25. Rabinovitch M, Molossi S, Clausell N. Cytokine mediated fibronectin production and transendothelial migration of lymphocytes in the mechanism of cardiac allograft vascular disease: efficacy of novel therapeutic approaches. J Heart Lung Transplant 1995;14:S116-S123.
26. Hauptman PJ, Nakagawa T, Tanaka H, Libby P. Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease?. J Heart Lung Transplant 1995;14:S173-S180.
27. Loskutoff DJ, van Aken BE, Seiffert D. Abnormalities in the fibrinolytic system of the vascular wall associated with atherosclerosis. Ann New York Acad Sci 1995;748:177-183.
28. Chakrabarti R, Hocking E, Fearnley G, Mann R, Atwell T, Jackson K. Fibrinolytic activity and coronary-artery disease. Lancet 1968;1:987-990.
29. Booth RF, Martin JF, Honey AC, Hassall DG, Beesley JE, Moncada S. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Arteriosclerosis 1989;76:257-268.
30. Pels K, Labinaz M, Garvin MR, Hoffert C, O'Brien ER. Arterial wall neovascularization after balloon injury: relationship to lumenal area. Can J Cardiol 1996;12:148E. (abstract).
31. Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells: expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 1996;78:405-414.
32. Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990;67:61-67.
33. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. [Review]. Bioessays 1993;15:105-111.
34. Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann New York Acad Sci 1992;667:141-150.
35. Shi Y, Pieniek M, Fard A, O'Brien J, Mannion JD, Zalewski A. Adventitial remodeling after coronary arterial injury. Circulation 1996;93:340-348.
36. Biemond B, Levi M, Ten Cate H, Van der Poll T, Buller H, Hack C, Ten Cate J. Plasminogen activator and plasminogen activator inhibitor type 1 release during experimental endotoxaemia in chimpanzees: effect of interventions on the cytokine and coagulation cascade. Clin Sci 1995;88:587-594.
37. Levi M, Wilmink J, Buller HR, Surachno J, Ten Cate J. Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Analysis of the defect and beneficial effect of fish-oil. Transplantation 1992;54:978-983.